Search

4-O-Demethylpenclomedine

AGS-004

A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient. … Non-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do not provide antiviral protection against the

Sulfisoxazole

A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.

Methylergometrine

A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)

Isatoribine

Isatoribine is a selective agonist of TLR7.

G4460

GLB-001

GLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).[L56124, L56125, L56126]

LJP 1082

The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I. … LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1.

Nelipepimut-S

Retifanlimab

On October 2021, Incyte Biosciences withdrew its application for a marketing authorization of retifanlimab for the treatment of squamous carcinoma of the anal canal. … By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells.